
Prof. Joo-Yong Hahn, Young Bin Song, Ki Hong Choi
A research team led by Professors Joo-Yong Hahn, Young Bin Song, and Ki Hong Choi of the Division of Cardiology at Samsung Medical Center, Sungkyunkwan University School of Medicine, together with Professor Yong Hwan Park of Samsung Changwon Hospital, has demonstrated that clopidogrel is more effective than aspirin as a long-term antiplatelet therapy in patients at high risk of recurrent cardiovascular events after coronary stent implantation. The findings come from the SMART-CHOICE 3 trial, a large, multicenter randomized clinical study conducted at 26 hospitals across South Korea, and were recently published in The Lancet, one of the world’s most influential medical journals. [Addressing an Unresolved Question in Long-Term Care After PCI] After percutaneous coronary intervention (PCI) with drug-eluting stents, patients typically receive dual antiplatelet therapy (DAPT) for a fixed period to prevent thrombotic complications. While this early treatment strategy is well established, the optimal choice of single antiplatelet therapy for long-term maintenance after completion of DAPT has remained uncertain.
2026-02-05